

# Scholar Rock to Host Conference Call to Discuss Third Quarter 2023 Financial Results and Provide Business Update on November 7, 2023

October 23, 2023

CAMBRIDGE, Mass.--(<u>BUSINESS WIRE</u>)--Scholar Rock (NASDAQ: SRRK), a Phase 3, clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundamental role, today announced that management will host a conference call to discuss its third quarter 2023 financial results and provide a business update on Tuesday, November 7, 2023, at 8:00 a.m. ET.

To access the conference call by phone, participants may register here to receive the dial-in number and unique PIN. A live webcast of the conference call will be available on the Investors & Media section of the Scholar Rock website at <a href="http://investors.scholarrock.com">http://investors.scholarrock.com</a>. An archived replay of the webcast will be available for approximately 90 days following the call.

#### **About Scholar Rock**

Scholar Rock is a clinical-stage biopharmaceutical company focused on the discovery and development of innovative medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. Scholar Rock is creating a pipeline of novel product candidates with the potential to transform the lives of patients suffering from a wide range of serious diseases, including neuromuscular disorders, cancer, and fibrosis. Scholar Rock's approach to targeting the molecular mechanisms of growth factor activation enabled it to develop a proprietary platform for the discovery and development of monoclonal antibodies that locally and selectively target these signaling proteins at the cellular level. By developing product candidates that act in the disease microenvironment, the Company intends to avoid the historical challenges associated with inhibiting growth factors for therapeutic effect. Scholar Rock believes its focus on biologically validated growth factors may facilitate a more efficient development path. For more information, please visit <a href="https://www.linkedin.com/company/scholar-rock/">www.ScholarRock.com</a> or follow Scholar Rock on Twitter (@ScholarRock) and LinkedIn (<a href="https://www.linkedin.com/company/scholar-rock/">https://www.linkedin.com/company/scholar-rock/</a>).

### **Availability of Other Information About Scholar Rock**

Investors and others should note that we communicate with our investors and the public using our company website <a href="https://www.scholarrock.com">www.scholarrock.com</a>, including, but not limited to, company disclosures, investor presentations and FAQs, Securities and Exchange Commission filings, press releases, public conference call transcripts and webcast transcripts, as well as on Twitter and LinkedIn. The information that we post on our website or on Twitter or LinkedIn could be deemed to be material information. As a result, we encourage investors, the media and others interested to review the information that we post there on a regular basis. The contents of our website or social media shall not be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended.

Scholar Rock® is a registered trademark of Scholar Rock, Inc.

## **Contacts**

Scholar Rock: Investors Rushmie Nofsinger Scholar Rock rnofsinger@scholarrock.com ir@scholarrock.com 857-259-5573

#### Media

Molly MacLeod Scholar Rock mmacleod@scholarrock.com media@scholarrock.com 802-579-599